I guess its just amazing that when the Invex announcement came regarding the "Granted European Orphan Drug Designation for TBI", the share price spiked from 38 cents to 60 cents.
Now the company is worth less than the cash in the company. Cash burn should also slow down going forward. Maybe no possibility of other opportunities arising for this company.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 84879 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 7400 | 2 |
View Market Depth
| Last trade - 16.12pm 11/11/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable